Roche Holding AG banner

Roche Holding AG
SIX:ROG

Watchlist Manager
Roche Holding AG Logo
Roche Holding AG
SIX:ROG
Watchlist
Price: 311.3 CHF -0.22%
Market Cap: CHf251.9B

Net Margin

20.9%
Current
Improving
by 3.3%
vs 3-y average of 17.6%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
20.9%
=
Net Income
CHf12.9B
/
Revenue
CHf61.5B

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
20.9%
=
Net Income
CHf12.9B
/
Revenue
CHf61.5B

Peer Comparison

Country Company Market Cap Net
Margin
CH
Roche Holding AG
SIX:ROG
248.4B CHF
Loading...
US
Eli Lilly and Co
NYSE:LLY
879.7B USD
Loading...
US
Johnson & Johnson
NYSE:JNJ
574.1B USD
Loading...
US
Merck & Co Inc
NYSE:MRK
295.2B USD
Loading...
CH
Novartis AG
SIX:NOVN
229.9B CHF
Loading...
US
Amgen Inc
NASDAQ:AMGN
183.3B USD
Loading...
US
Pfizer Inc
NYSE:PFE
154.1B USD
Loading...
DE
Bayer AG
XETRA:BAYN
38.6B EUR
Loading...
UK
AstraZeneca PLC
LSE:AZN
232B GBP
Loading...
IE
Endo International PLC
LSE:0Y5F
244.4B USD
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1T DKK
Loading...

Market Distribution

Higher than 81% of companies in Switzerland
Percentile
81st
Based on 1 179 companies
81st percentile
20.9%
Low
-57 027.8% — 1.3%
Typical Range
1.3% — 13.7%
High
13.7% — 3 663.7%
Distribution Statistics
Switzerland
Min -57 027.8%
30th Percentile 1.3%
Median 7.2%
70th Percentile 13.7%
Max 3 663.7%

Roche Holding AG
Glance View

Roche Holding AG, a titan in the world of healthcare, operates from its headquarters in Basel, Switzerland. Established in 1896, Roche has grown into one of the world's leading pharmaceutical and diagnostics companies, driven by a steadfast commitment to advancing medicine and improving lives. Its unique business model is built on two primary pillars: Pharmaceuticals and Diagnostics. The pharmaceutical division focuses on discovering and developing medicines for cancer, immunology, infectious diseases, ophthalmology, and diseases of the central nervous system. A significant portion of its revenue is generated from innovative oncology drugs, which positions Roche as a global leader in cancer treatment. The company's investment in research and development is notably high, emphasizing its dedication to scientific discovery. On the diagnostics front, Roche continually advances its technologies to enhance disease detection and monitoring. This division creates and sells a wide array of diagnostic products and services, ranging from clinical chemistry and immunoassays to molecular biology and tissue diagnostics. By serving hospitals, research labs, and healthcare professionals, Roche Diagnostics aims to make a crucial impact on patient care and health system efficiency. This dual focus on pharmaceuticals and diagnostics allows Roche to capitalize on synergies between drug development and patient diagnostics, often integrating their advancements to provide more tailored and efficient healthcare solutions. The company's financial strength and strategic innovation are underpinned by its ability to adapt to changing market dynamics, ensuring its place as a stalwart in the global healthcare industry.

ROG Intrinsic Value
LOCKED
Unlock
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
20.9%
=
Net Income
CHf12.9B
/
Revenue
CHf61.5B
What is Roche Holding AG's current Net Margin?

The current Net Margin for Roche Holding AG is 20.9%, which is above its 3-year median of 17.6%.

How has Net Margin changed over time?

Over the last 3 years, Roche Holding AG’s Net Margin has increased from 19.6% to 20.9%. During this period, it reached a low of 13.7% on Dec 31, 2024 and a high of 20.9% on Jan 1, 2026.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett